厄洛替尼
外觀
臨床資料 | |
---|---|
商品名 | Tarceva |
AHFS/Drugs.com | Monograph |
MedlinePlus | a605008 |
核准狀況 | |
給藥途徑 | Oral tablets |
ATC碼 | |
法律規範狀態 | |
法律規範 |
|
藥物動力學數據 | |
生物利用度 | 59% |
血漿蛋白結合率 | 95% |
藥物代謝 | Hepatic (mainly CYP3A4, less CYP1A2) |
生物半衰期 | 36.2 hrs (median) |
排泄途徑 | >98% as metabolites, of which >90% via faeces, 9% via urine |
識別資訊 | |
| |
CAS號 | 183321-74-6 |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.216.020 |
化學資訊 | |
化學式 | C22H23N3O4 |
摩爾質量 | 393.44 g·mol−1 |
3D模型(JSmol) | |
| |
|
厄洛替尼(英語:Erlotinib,商品名:Tarceva,特羅凱)是用於治療非小細胞肺癌(NSCLC)、胰腺癌等幾種癌症的藥物,作為一種酪氨酸激酶抑制劑作用於表皮生長因子受體,由羅氏公司生產。
藥物合成
[編輯]- 第一種合成路徑
- 第二種合成路徑
參考文獻
[編輯]外部連結
[編輯]- Official Tarceva website (頁面存檔備份,存於互聯網檔案館)
- Tarceva Discussion Group for Cancer Patients (頁面存檔備份,存於互聯網檔案館)
- Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. August 2004, 305 (5687): 1163–7. PMID 15284455. doi:10.1126/science.1101637..
- Genzyme "Genzyme Launches Exclusive Lung Cancer Test" Press Release September 27, 2005
- "Determinants of Tumor Response and Survival With Erlotinib in Patients With Non-Small-Cell Lung Cancer (頁面存檔備份,存於互聯網檔案館), Journal of Clinical Oncology, August 15, 2004.
- October 2003 issue of Lung Cancer Frontiers on rash/effectiveness correlation
- FAQ: I started an EGFR inhibitor two weeks ago but haven’t developed a rash. Does this mean it’s not working?, Dr. Howard L. (Jack) West, M.D., GRACE(頁面存檔備份,存於互聯網檔案館), February 21, 2011 (directed toward the layperson).
- http://www.cancer.gov/clinicaltrials/results/lung-and-erlotinib0604l[永久失效連結]
- https://web.archive.org/web/20081012081613/http://www.roche.com/med-cor-2007-10-22
- https://web.archive.org/web/20110726060413/http://www.roche.com/med-cor-2009-05-30b
- https://web.archive.org/web/20120918193637/http://www.cipla.com/whatsnew/news.htm#27apr09
- https://web.archive.org/web/20120918193637/http://www.cipla.com/whatsnew/news.htm#20mar08
|